Literature DB >> 28599823

Neuropathy and presence of emotional distress and depression in longstanding diabetes: Results from the Canadian study of longevity in type 1 diabetes.

Johnny-Wei Bai1, Leif E Lovblom1, Marina Cardinez1, Alanna Weisman1, Mohammed A Farooqi1, Elise M Halpern1, Genevieve Boulet1, Devrim Eldelekli1, Julie A Lovshin1, Yuliya Lytvyn2, Hillary A Keenan3, Michael H Brent4, Narinder Paul5, Vera Bril6, David Z I Cherney2, Bruce A Perkins7.   

Abstract

AIM: To determine the association of neuropathy and other complications with emotional distress and depression among patients with longstanding type 1 diabetes (T1DM).
METHODS: Canadians with ≥50years of T1DM completed a questionnaire including assessment of distress and depression by the Problem Areas in Diabetes Scale (PAID) and Geriatric Depression Scale (GDS), respectively. Complications were determined using the Michigan Neuropathy Screening Instrument (Questionnaire Component), fundoscopy reports, renal function tests, and self-reported peripheral-(PVD) and cardiovascular (CVD) disease. Associations were analyzed by Poisson regression.
RESULTS: Among 323 participants, 137 (42.4%) had neuropathy, 113 (36.5%) nephropathy, 207 (69.5%) retinopathy, 95 (29.4%) CVD, and 31 (9.8%) PVD. The neuropathy subgroup had higher prevalence of distress (13 (9.5%) vs. 6 (3.3%), p=0.029) and depression (34 (24.9%) vs. 12 (6.5%), p<0.001). Adjusting for diabetes complications, neuropathy was associated with higher PAID (adjusted RR 1.44 (95% CI 1.14-1.82), p=0.003) and GDS scores (adjusted RR1.57 (1.18-2.11), p=0.002). Independent of potential confounders, neuropathy remained associated with higher PAID (adjusted RR 1.39 (1.10-1.76), p=0.006) and GDS scores (adjusted RR 1.37 (1.03-1.83), p=0.032). Associations with neuropathy were not fully explained by neuropathic pain.
CONCLUSION: Compared to other complications, neuropathy had the greatest association with distress and depression in longstanding T1DM, independent of pain. Strategies beyond pain management are needed to improve quality of life in diabetic neuropathy.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Complications; Depression; Distress; Neuropathy; Psychology; Type 1 diabetes

Mesh:

Year:  2017        PMID: 28599823     DOI: 10.1016/j.jdiacomp.2017.05.002

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  8 in total

1.  The hidden costs of painful diabetic neuropathy revealed.

Authors:  A Gordon Smith; Saša Živković
Journal:  Neurol Clin Pract       Date:  2019-10-29

2.  Lower corneal nerve fibre length identifies diabetic neuropathy in older adults with diabetes: results from the Canadian Study of Longevity in Type 1 Diabetes.

Authors:  Daniel Scarr; Leif E Lovblom; Julie A Lovshin; Geneviève Boulet; Mohammed A Farooqi; Andrej Orszag; Alanna Weisman; Nancy Cardinez; Yuliya Lytvyn; Mylan Ngo; Hillary A Keenan; Michael H Brent; Narinder Paul; Vera Bril; David Z I Cherney; Bruce A Perkins
Journal:  Diabetologia       Date:  2017-10-03       Impact factor: 10.122

3.  Long non-coding RNA MSTRG.81401 short hairpin RNA relieves diabetic neuropathic pain and behaviors of depression by inhibiting P2X4 receptor expression in type 2 diabetic rats.

Authors:  Mengyun Sun; Mingming Zhang; Haoming Yin; Hongcheng Tu; Yuqing Wen; Xingyu Wei; Wenhao Shen; Ruoyu Huang; Wei Xiong; Guodong Li; Yun Gao
Journal:  Purinergic Signal       Date:  2022-01-13       Impact factor: 3.765

4.  Risk factors for depression and anxiety in painful and painless diabetic polyneuropathy: A multicentre observational cross-sectional study.

Authors:  David Kec; Aneta Rajdova; Jana Raputova; Blanka Adamova; Iva Srotova; Eva Kralickova Nekvapilova; Radka Neuzilova Michalcakova; Magda Horakova; Jana Belobradkova; Jindrich Olsovsky; Pavel Weber; Gabriel Hajas; Michaela Kaiserova; Radim Mazanec; Veronika Potockova; Edvard Ehler; Martin Forgac; Frank Birklein; Nurcan Üçeyler; Claudia Sommer; Josef Bednarik; Eva Vlckova
Journal:  Eur J Pain       Date:  2021-10-10       Impact factor: 3.651

5.  Estimating GFR by Serum Creatinine, Cystatin C, and β2-Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes.

Authors:  Daniel Scarr; Petter Bjornstad; Leif E Lovblom; Julie A Lovshin; Genevieve Boulet; Yuliya Lytvyn; Mohammed A Farooqi; Vesta Lai; Andrej Orszag; Alanna Weisman; Hillary A Keenan; Michael H Brent; Narinder Paul; Vera Bril; David Z I Cherney; Bruce A Perkins
Journal:  Kidney Int Rep       Date:  2019-02-21

6.  Validity and reliability of a point-of-care nerve conduction device in diabetes patients.

Authors:  Yuka Shibata; Tatsuhito Himeno; Taeko Kamiya; Hiroya Tani; Takayuki Nakayama; Chika Kojima; Yukako Sugiura-Roth; Ena Naito; Masaki Kondo; Shin Tsunekawa; Yoshiro Kato; Jiro Nakamura; Hideki Kamiya
Journal:  J Diabetes Investig       Date:  2019-02-08       Impact factor: 4.232

7.  Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes.

Authors:  Sandra Sif Gylfadottir; Diana Hedevang Christensen; Sia Kromann Nicolaisen; Henning Andersen; Brian Christopher Callaghan; Mustapha Itani; Karolina Snopek Khan; Alexander Gramm Kristensen; Jens Steen Nielsen; Søren Hein Sindrup; Niels Trolle Andersen; Troels Staehelin Jensen; Reimar Wernich Thomsen; Nanna Brix Finnerup
Journal:  Pain       Date:  2020-03       Impact factor: 7.926

8.  Diabetic polyneuropathy with/out neuropathic pain in Mali: A cross-sectional study in two reference diabetes treatment centers in Bamako (Mali), Western Africa.

Authors:  Youssoufa Maiga; Salimata Diallo; Fatoumata Dite Nènè Konipo; Oumar Sangho; Modibo Sangaré; Seybou H Diallo; Saliou Mahamadou; Yann Péréon; Bernard Giumelli; Awa Coulibaly; Mariam Daou; Zoumana Traoré; Djeneba Sow Sylla; Mohamed Albakaye; Cheick Oumar Guinto; Madani Ouologem; Adama S Sissoko; Hamar A Traoré; Souleymane Papa Coulibaly; Philippe Damier; Nadine Attal; Julien Nizard
Journal:  PLoS One       Date:  2020-11-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.